Amylyx Pharmaceuticals Inc (AMLX)
2.005
+0.08
(+3.89%)
USD |
NASDAQ |
May 02, 16:00
2.005
0.00 (0.00%)
After-Hours: 18:32
Amylyx Pharmaceuticals Research and Development Expense (Quarterly): 44.91M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 44.91M |
| September 30, 2023 | 30.04M |
| June 30, 2023 | 29.04M |
| March 31, 2023 | 24.19M |
| December 31, 2022 | 22.81M |
| September 30, 2022 | 24.91M |
| June 30, 2022 | 24.26M |
| Date | Value |
|---|---|
| March 31, 2022 | 21.46M |
| December 31, 2021 | 13.39M |
| September 30, 2021 | 12.85M |
| June 30, 2021 | 10.93M |
| March 31, 2021 | 6.864M |
| December 31, 2020 | 5.013M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.013M
Minimum
Dec 2020
44.91M
Maximum
Dec 2023
20.82M
Average
22.81M
Median
Dec 2022
Research and Development Expense (Quarterly) Benchmarks
| Cassava Sciences Inc | 18.73M |
| iRhythm Technologies Inc | 15.42M |
| Bristol-Myers Squibb Co | 2.695B |
| Moderna Inc | 1.406B |
| ACADIA Pharmaceuticals Inc | 66.74M |